Holen Sie sich die Stockscreener-App
1.92
2.54%
-0.05
Handel nachbörslich:
1.92
Schlusskurs vom Vortag:
$1.97
Offen:
$1.97
24-Stunden-Volumen:
78,057
Relative Volume:
0.70
Marktkapitalisierung:
$279.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-8.5447
EPS:
-0.2247
Netto-Cashflow:
-
1W Leistung:
-2.04%
1M Leistung:
+0.52%
6M Leistung:
-18.30%
1J Leistung:
-13.90%
1-Tages-Spanne:
$1.88
$1.98
1-Wochen-Bereich:
$1.88
$2.08
52-Wochen-Spanne:
$1.66
$3.335
Immutep Limited Adr Stock (IMMP) Company Profile
Firmenname
Immutep Limited Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IMMP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
1.92 | 279.28M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-17 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-07-16 | Fortgesetzt | Maxim Group | Buy |
| 2018-09-28 | Eingeleitet | B. Riley FBR | Buy |
| 2018-02-15 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Immutep Limited Adr Aktie (IMMP) Neueste Nachrichten
Immutep Quarterly Activities Report Q2 FY25 - GlobeNewswire Inc.
Immutep Limited (NASDAQ:IMMP) Shares Sold by Jane Street Group LLC - Defense World
Verition Fund Management LLC Has $57,000 Stock Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - The Manila Times
Immutep shares new cancer study results - Investing.com
Immutep Quarterly Activities Report Q1 FY25 - Yahoo Finance
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial - The Manila Times
Immutep Limited ADR (IMMP) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Metric Deep Dive: Understanding Immutep Limited ADR (IMMP) Through its Ratios - The Dwinnex
Immutep reports positive results in cancer study - Investing.com
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga
Research Analysts Issue Forecasts for Immutep Limited’s FY2025 Earnings (NASDAQ:IMMP) - Defense World
Immutep Limited ADR (IMMP) Stock: Navigating a Year of Volatility - The InvestChronicle
Short Interest in Immutep Limited (NASDAQ:IMMP) Declines By 10.1% - Defense World
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody - GlobeNewswire
Immutep reports steady progress in Q4 FY24 - Investing.com
Immutep reports steady progress in Q4 FY24 By Investing.com - Investing.com Australia
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer - GlobeNewswire
Immutep Receives Regulatory Clearance for Phase I Study of - GlobeNewswire
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Stocks of the Hour: Adherium, Nanoveu, Nimy Resources - ShareCafe
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 - GlobeNewswire
10 Best Australian Stocks To Buy - Yahoo Finance
Immutep LimitedADR (IMMP) Price Target Increased by 7.83% to 2.80 - MSN
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer - GlobeNewswire
Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - Targeted Oncology
Best Penny Stocks To Buy For 2021? 5 Biotech Stocks To Watch - Penny Stocks
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO - Yahoo Finance
Immutep (IMMP) Stock Price, News & Analysis - MarketBeat
Finanzdaten der Immutep Limited Adr-Aktie (IMMP)
Es liegen keine Finanzdaten für Immutep Limited Adr (IMMP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):